Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Completed · Phase 4 · NCT05969223

Conditions: Genital Psoriasis, Scalp Psoriasis

Research payments reported, 2025: $616,862
U.S. investigators named: 31
Sites paid: 38
Planned or actual enrollment: 214

About the trial

Sponsor: AbbVie
Tested: Risankizumab (drug), Placebo for Risankizumab (drug)
Dates: Started 2023-08-10; completion 2025-11-28
Results posted: Yes

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will b…

From ClinicalTrials.gov, last updated 2026-02-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $616,862 in research payments for this study in 2025 (220 payments).

Products named: Skyrizi

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it